Type of information: Licensing agreement
Company: MeiraGTx (USA - NY) National Institute of Dental and Craniofacial Research (NIDCR) (USA)
Therapeutic area: Rare diseases
Type agreement: licensing
Action mechanism: gene therapy.
Disease: Sjögren’s syndrome and associated xerostomia or xerophthalmia
- • On October 31, 2018, MeiraGTx announced an exclusive licensing agreement with the National Institute of Dental and Craniofacial Research (NIDCR), a division of the National Institutes of Health (NIH). Under the agreement, MeiraGTx will receive worldwide rights to adeno-associated virus vector mediated gene delivery of aquaporin-1, designated AAV-AQP1, for Sjögren’s syndrome patients with associated xerostomia (dry mouth) or xerophthalmia (dry eyes). The license agreement includes standard and customary US Government terms and provisions.
- MeiraGTx and the NIDCR are currently partnered in two cooperative research and development agreements (CRADAs), one supporting preclinical work investigating AAV-AQP1 as a treatment for inadequate salivary gland function associated with Sjögren’s syndrome, and the other covering an ongoing Phase 1 dose escalation clinical study of AAV-AQP1 in patients with grade 2 or 3 radiation-induced xerostomia.